Developing new treatments targeting HDAC11 for autoimmune diseases like multiple sclerosis
Design and development of HDAC11-specific chemical inhibitors for disease treatments
This study is looking at a special enzyme called HDAC11 to see how it affects autoimmune diseases like multiple sclerosis, with the goal of creating new treatments that could help people living with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11035147 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific enzyme, HDAC11, in autoimmune diseases such as multiple sclerosis (MS). The team aims to create chemical inhibitors that specifically target HDAC11, which may lead to new treatment options for patients suffering from MS and similar conditions. By studying the effects of inhibiting HDAC11, the researchers hope to uncover new biological mechanisms that contribute to the disease and improve therapeutic strategies. The research involves both laboratory studies and the development of new compounds that could potentially be tested in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis or other related autoimmune disorders.
Not a fit: Patients with autoimmune conditions not related to the central nervous system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with multiple sclerosis and other autoimmune diseases.
How similar studies have performed: Other research has shown promise in targeting similar pathways in autoimmune diseases, suggesting potential for success with this novel approach.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Seto, Edward — George Washington University
- Study coordinator: Seto, Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.